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Abstract 15 
While proving highly effective in controlling Anthrax in farm animals all over the world currently 16 
attenuated live anthrax vaccines employed in a veterinary context suffer from drawbacks such as 17 
residual virulence, short term protection, variation in quality and, most importantly, lack of efficacy 18 
if administered simultaneously with antibiotics. These limitations have stimulated the development 19 
of non-living component vaccines which induce a broad spectrum immune response capable of 20 
targeting both toxaemia (as in the case of PA based vaccines) and bacteraemia. To contribute to this 21 
several new approaches were tested in outbred NMRI mice for antibody titres and protectiveness. 22 
Plasmids encoding a recombinant toxin derived fusion peptide and a spore surface derived peptide 23 
were tested as DNA-vaccines in comparison to their protein counterparts utilising two adjuvant 24 
approaches and two DNA-vector backbones. The combination of two plasmids encoding 25 
2 
LFD1PAD4-mIPS1 and TPA-BclAD1D3-LAMP1, when delivered by GeneGun, protected 90% of 26 
the animals against a lethal challenge with 25LD50 spores of the Ames strain of Bacillus anthracis. 27 
Single applications of either antigen component showed significantly lower protection rates, 28 
indicating the beneficial interaction between anti-spore and anti-toxin components for an acellular 29 
vaccine formulation. 30 
31 
1. Introduction32 
Anthrax is caused by Bacillus anthracis, a Gram-positive, spore forming, rod-shaped bacterium [1]. 33 
Spores gain access via cutaneous, oral or inhalational routes where they germinate and develop into 34 
vegetative bacilli which then replicate and produce toxins which eventually kill the host [2]. The 35 
pathogen expresses two major plasmid encoded virulence factors, a gamma-linked poly-D-glutamic 36 
acid capsule (pX02 [3]) and a tripartite toxin (pX01 [4]) comprised of Protective Antigen (PA)
1
,37 
Lethal Factor (LF)
2
 and Edema Factor (EF)
3
 [5][6].38 
Current live attenuated veterinary anthrax vaccines are less than ideal. They can cause problems in 39 
sensitive animals such as goats and llamas, protection is short term, variation in vaccine quality can 40 
cause vaccine failure and most importantly the live nature of the vaccine prevents its efficacy if 41 
delivered at the same time as antibiotics [7][8]. These limitations have stimulated the development 42 
of non-living, component vaccines capable of inducing a broad spectrum immune response which 43 
targets both toxaemia and bacteraemia. 44 
The strong correlation between toxin neutralising activity (tna)
4
of PA-specific antibodies and 45 
protection [9] has prompted efforts to develop vaccines based solely on domains which stimulate  46 
antibodies with tna [10][11][12]. One such study which employed a fusion protein comprised of 47 
domain 4 of PA (receptor binding site) and domain 1 of LF (PA binding site) protected mice against 48 
1 PA – Protective Antigen 
2 LF – Lethal Factor 
3 EF – Edema Factor 
4 tna – toxin neutralising activity 
3 
a subsequent lethal challenge with B. anthracis spores [13]. To further assess the immunogenic 49 
value of this protein we administered it as a DNA-vaccine in two different vectors and compared its 50 
activity to that seen against full length rPA83. 51 
In addition to neutralising the action of toxins the spore can also be targeted to prevent the pathogen 52 
from gaining a foothold in the infected individual [14][15]. Vaccination experiments with live 53 
nonvirulent or formaldehyde-inactivated spores have shown that spore specific immune responses 54 
can enhance the level of protection when given in combination with PA [16]. 55 
56 
One such component is the Bacillus collagen like protein of anthracis (BclA)
5
 which forms hair-57 
like structures projecting from the spore surface and represents a major spore immunogen [17][18]. 58 
The removal of the collagen-like region (CLR
6
, domain 2) from BclA has no detrimental effect on59 
immunogenicity and results in a smaller peptide which is easier to incorporate into a 60 
multicomponent vaccine [19][20]. In this study we determined the immunogenicity of a CLR-61 
deficient version of BclA called rBclAD1D3 when administered as a DNA-vaccine in two different 62 
vectors. 63 
64 
For the DNA vaccine studies we employed two different plasmid backbones (pDNAVaccUltra and 65 
NTC7382) which varied with regards to intracellular routing signals and immune stimulatory 66 
elements [21]. To improve in vivo antigen presentation we utilised intracellular routing signals 67 
which directed vaccine peptides to the MHC I and MHC II pathways. To target the MHC II 68 
pathway [22] we employed tissue plasminogen activator (TPA)
7
 which routes newly expressed69 
proteins to the secretion pathway [23] and lysosome-associated membrane protein (LAMP1)
8
 which70 
directs proteins to the endosome [24][25]. To enhance MHC I presentation we employed ubiquitin 71 
5 BclA – Bacillus collagen like protein of anthracis 
6 CLR –  collagen-like region 
7 TPA – tissue plasminogen activator 
8 LAMP1 – lysosome-associated membrane protein 
4 
which directs the associated protein to the proteasome [26][27]. 72 
73 
To enhance the immunogenicity of the expressed proteins we investigated the utility of two 74 
molecular adjuvants. Mouse interferon-ß promoter stimulator 1 (mIPS-1)
9
 incorporated into the75 
backbone of the antigen encoding plasmid significantly induces type I interferon and interferon-76 
stimulated genes in a TLR-independent matter [28][29][30]. Mouse class II MHC trans-activator 77 
(CIITA)
10
 up-regulates MHC expression [31][32] and was co-administered on a separate plasmid.78 
In comparison to the DNA vaccines, full length rPA and rBclA were tested as proteins alone and in 79 
combination in the presence of a previously tested and approved lipopeptide adjuvant comprising 80 
Pam3Cys-SKKKK, a TLR2/1 activator admixed with Pam3Cys conjugated to the promiscuitive T-81 
helper-cell epitope of the sperm whale myoglobin SFISEAIIHVLHSRHPG [33][34]. 82 
The overall aim of this study was to determine the ability of BclA to confer additional 83 
protectiveness when given together with a toxin-specific vaccine. 84 
85 
86 
2. Material and Methods87 
2.1. Antigen preparation 88 
E. coli BL21-CodonPlus-RIL cells (Stratagene, La Jolla, CA) harboring the plasmid pREP 489 
(Qiagen, Venlo, Netherland) and pQE-30 (Qiagen) encoding either rPA83, rBclA or rLF were grown 90 
and purified as described previously [35]. Proteins used for ELISA received no further treatment 91 
while proteins used for vaccination were tested for endotoxin using the Limulus Amoebocyte Lysate 92 
Endochrome-K test kit (Charles River, Wilmington, MA) as described by the manufacturer. 93 
Endotoxin removal was performed via EndoTrap blue endotoxin removal system (Hyglos, Bernried, 94 
Germany). 95 
9 mIPS-1 – mouse interferon-ß promoter stimulator 1 
10 CIITA – mouse class II MHC trans-activator 
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96 
2.2. Preparation of DNA-vaccines 97 
Providing of vector-backbones (pDNAVaccUltra and NTC7382) including signal sequences, 98 
cloning of respective gene sequences and purification of the constructs was undertaken by the 99 
Nature Technology Corporation (Lincoln, NE). The sequence for murine CIITA (Mn01492) was 100 
acquired from GeneCopoeia (Rockville, MD) and the sequence of mIPS-1 was used as given for 101 
pUNO1-mIPS1 (Genebank: NM_144888.2). Antigens used comprised of rPA83 (2208 bp) [35], 102 
LFD1PAD4 (1300 bp) [13] and BclAD1D3 (480 bp) [20]. Vaccines were prepared and applied as 103 
described previously [35]. 104 
105 
2.3. Administration of vaccines and challenge 106 
Trials were performed using 8-12 weeks old female outbred NMRI mice (Charles River). 107 
Immunisation groups comprised of 10 animals, while groups which only received an adjuvant 108 
(lipopeptide or CIITA) contained 5 individuals. 109 
Mice were immunised 3 times at intervals of 2 weeks. Challenge was performed 3 weeks after the 110 
last immunisation and mice were monitored for survival for up to 4 weeks. Blood was taken prior to 111 
immunisation, before challenge and after the end of the challenge. All data presented is referring to 112 
sera taken before the challenge unless stated otherwise. Preparation, vaccination and challenge of 113 
the mice was performed under anesthesia with Isofluran (Actavis, Weiterstadt, Germany) using a 114 
ventilated Box. 115 
Mice immunised with protein received a 200 µl dose s.c. in the neck containing 25 µg of each 116 
antigen and 50 µg of the lipopeptide adjuvant (EMC microcollections, Tuebingen Germany) diluted 117 
in sterile endotoxin free PBS (Sigma-Aldrich, St. Louis, MO). Mice immunised with DNA-vaccines 118 
were shaved 1-2 days before the immunisation. Each mouse received 2 cartridges containing a total 119 
of 3 µg of DNA (6 µg for the combination) per immunisation applied via GeneGun (tab 1). For the 120 
6 
challenge, a dose of 200 µl of a fully virulent Ames strain containing ~1000 spores (25LD50) for all 121 
DNA-vaccines and ~2000 spores (50LD50) for all protein vaccines was administered s.c. in the 122 
neck. The increased challenge dose for the protein vaccines was utilised due to the residual 123 
protectiveness of the lipopeptide alone observed when challenged with lower spore doses (data not 124 
shown), thus normalising its effect to allow for a better discrimination between different antigens 125 
and applications. Mice that died during the challenge or were killed via CO2 after the end of the 126 
challenge were dissected to prepare liver and spleen which were then plated on blood agar to verify 127 
the presence of the pathogen. 128 
129 
2.4. Serology 130 
ELISA was performed as described previously [35]. Secondary antibodies comprised of horseradish 131 
peroxidase conjugated polyclonal goat anti-mouse IgG (Sigma-Aldrich), IgG1 and IgG2a (Acris, 132 
San Diego, CA). Endpoint titres were defined as the reciprocal of the highest serum dilution that 133 
resulted in an absorbance greater than two standard deviations above the average of the negative 134 
control serum sample (pooled naive sera of the according group) with a minimum OD414nm value of 135 
0.1. 136 
Sera were analysed for neutralising antibody titres via in vitro toxin neutralising assay (TNA) as 137 
published previously [35]. The neutralisation titre (NT) corresponds to the inverse serum dilution at 138 
which the toxin neutralisation yielded 50% (NT50). The NT50 was estimated using the SigmaPlot 139 
regression wizard (4-parameter sigmoid regression curve). Detailed Titres are only described for 140 
sera taken before the challenge. 141 
142 
2.5. Statistics 143 
Estimated antibody titres of different groups were compared via Mann-Whitney U-test. Survival 144 
rates were analysed through log rank test, taking full days survived into consideration. Correlations 145 
7 
between titres and titres and survival were estimated via spearman-rank correlation test. For all 146 
statistical purposes a P-value of 0.05 and smaller was considered significant, resulting in a critical 147 
value of 0.564 for rs for quantities of 10. 148 
149 
3. Results and discussion150 
Addition of rBclA to rPA83 increased the level of protection when applied together as proteins 151 
Groups of mice vaccinated with either rPA83, rBclA or a combination of both together with 152 
lipopeptide adjuvant induced significant IgG antibody titres with a strong IgG1 emphasis against 153 
their respective antigens (fig. 1 and 2). The measured antibody titres as well as the NT50-titres 154 
(fig. 3) for the groups receiving either rPA83 or rBclA alone were similar to or higher than those 155 
seen in the group given both proteins suggesting no synergistic effects or shift in subclass 156 
dominance. 157 
Each antigen when given alone did not provide significant protection while the combination 158 
achieved 70% protection (tab. 1; fig. 4A) indicating that rBclA and rPA83 augment each others 159 
ability to protect. These findings are similar to those reported in a previous study where A/J mice 160 
were challenged with spores of the Sterne strain of B. anthracis [14]. The authors of this study 161 
concluded that BclA enhanced protection by inducing the opsonization of spores and stimulating the 162 
production of antibodies which also inhibited germination. In addition PA-specific antibodies have 163 
been shown to promote spore opsonization and the inhibition of germination in a similar manner to 164 
BclA [36]. Thus the protection seen in animals given rPA83 and rBclA may be the result of a 165 
synergy in the anti-spore effect rather than a feature of anti-toxin properties. This would explain 166 
why we saw no correlation between survival and antibody titres (rs ≤ ±0.53). This applied also to 167 
the NT50-titres of animals immunised with rPA83 as they had generated high toxin neutralising 168 
antibodies, a feature which has previously been shown to correlate with protection in other animal 169 
models [9][37][38][39]. However to our knowledge such a correlation has not been recorded for 170 
8 
outbred mice challenged with Ames. 171 
Comparison of the IgG subclass spectrum revealed a strong Th2 bias, with IgG1 titres equating IgG 172 
titres strongly (rs ≥ +0.81). Nonetheless significant, but highly scattered IgG2a antibody titres 173 
against both antigens were raised in the majority of the animals. 174 
175 
DNA-vectors encoding for toxin components were able to significantly protect outbred NMRI 176 
mice from lethal challenge 177 
In a previous study we reported that the fusion protein LFD1PAD4 was able to fully protect A/J 178 
mice against i.p. challenge with ~ 10
5
 spores of the Sterne vaccine strain [13]. To determine if a179 
similar level of protection could be achieved when the antigen was presented in the context of a 180 
DNA vaccine we introduced the gene encoding the fusion protein into two different DNA vectors 181 
and compared the resulting immune responses to those seen using a DNA vaccine expressing full 182 
length rPA83. The latter had been shown to significantly protect A/J mice from a lethal challenge 183 
with the attenuated STI-1 vaccine strain [35] but not outbred mice from challenge with spores of the 184 
fully virulent Ames strain [40]. 185 
The DNA-vaccines elicited significantly lower (1-2 log10) anti-PA-antibody and NT50-titres 186 
(fig. 1and 3) than the protein vaccines which contained rPA83 (tab 1). While the TPA-LFD1PAD4-187 
mIPS1 and TPA-rPA83-LAMP1 constructs stimulated similar anti-rPA83-IgG and -IgG1 titres they 188 
were significantly higher than those seen using TPA-LFD1PAD4-LAMP1 which failed to elicit anti-189 
rPA83 titres in the majority of the animals and thus was not distinctive of the pre-immune sera. 190 
Of the two DNA constructs which contained LF the TPA-LFD1PAD4-mIPS1 vector induced higher 191 
anti-rLF-IgG and -IgG1 titres (fig. 5) and for both constructs the LF specific antibody response 192 
before the challenge exceeded that seen against PA as has been noted previously [13]. A positive 193 
correlation between anti-rPA83- and anti-rLF-IgG titres to NT50-titres (rs ≥ +0.66) was seen for 194 
TPA-LFD1PAD4-mIPS1 suggesting that the fusion protein stimulated the production of toxin 195 
9 
neutralising antibodies. Indeed significant NT50-titres were only raised in individuals immunised 196 
with TPA-LFD1PAD4-mIPS1. With regards to the IgG subclass balance all of the DNA constructs 197 
failed to stimulate an IgG2a response for rPA83 and rLF indicating a strong Th2-specific immune 198 
response often seen with GeneGun applications [40][41][41] 199 
When challenged with 25LD50 of fully virulent Ames strain spores a level of protection of between 200 
30-40% was accomplished (tab. 1). Interestingly, only the surviving individuals immunised with201 
TPA-LFD1PAD4-LAMP showed a measurable anti-rPA83-IgG titre before the challenge whereas 202 
the individuals that succumbed to infection did not, resulting in a strong correlation of anti-rPA83-203 
IgG titres with survival (rs = +0.888). Furthermore, anti-rLF-IgG titres were induced in all animals 204 
and showed a correlation to survival (rs = +0.685) and anti-rPA83-IgG titres (rs = +0.885). A notable 205 
difference concerning the subclass bias of the two adjuvants tested (CIITA and mIPS-1) was not 206 
present since their mode of action results in an up-regulation of the MHC-genes neither favouring 207 
IgG1 nor IgG2a responses. However the variable immunogenicity of the different vectors might be 208 
attributed to the different adjuvants utilised. In conclusion the toxin vectors examined in this study 209 
elicited slightly lower PA-specific antibody titres than seen in an earlier study, but were equally 210 
protective [40]. 211 
212 
DNA-vectors encoding for BclAD1D3 possibly stimulated sterile immunity and protected 50% 213 
of the animals 214 
BclAD1D3 was cloned into two different DNA vaccine vectors, one in which the gene was flanked 215 
by TPA and LAMP1 and a second in which BclAD1D3 was directed to the proteasome by the 216 
incorporation of an N-terminal ubiquitin signal sequence. Both constructs elicited robust anti-217 
rBclA-IgG, -IgG1 and -IgG2a antibody responses (fig. 2) comparable to those seen for full length 218 
rBclA given as a protein. We saw no significant difference in the magnitude of the immune response 219 
for either DNA vaccine suggesting that the various routing signals had no detectable influence. The 220 
10 
only discernable difference between both concerned the IgG2a titres, which were detectable in all 221 
individuals immunised with TPA-BclAD1D3-LAMP1 but not when BclAD1D3-Ubiquitin was 222 
applied. It is possible that by using a GeneGun to deliver each DNA vaccine any beneficial effect 223 
provided by targeting routing was masked [41][42]. Our previous study with full length BclA 224 
applied via GeneGun in a vector containing a different secretion signal, depicted a similar antibody 225 
spectrum with a distinctive IgG1 bias [40]. 226 
Both of the vaccines tested in our study protected 50% of the animals when challenged with fully 227 
virulent spores (fig. 1B). Analysis of the blood of animals which have survived challenge gave the 228 
indication of a possible sterile infection as inferred from lack of PA antibodies [43]. To our 229 
knowledge the level of protection achieved in this study following immunisation with BclAD1D3 230 
exceeds that previously reported for BclA in protein or DNA vaccine form [14][40][44][20]. 231 
232 
A combined DNA vaccine comprising TPA-LFD1PAD4-mIPS1 and TPA-BclAD1D3-LAMP1 233 
stimulated significant protection against a lethal spore challenge 234 
To determine if we could further increase the level of protective immunity we co-immunised mice 235 
with TPA-LFD1PAD4-mIPS1 and TPA-BclAD1D3-LAMP1 and subjected them to a lethal spore 236 
challenge. The TPA-BclAD1D3-LAMP vector was selected for these studies as it had previously 237 
been reported that DNA-vectors containing ubiquitin reacted adversely in the presence of other 238 
DNA vector signal sequences [45]. Following a lethal spore challenge (25LD50) 90% of the animals 239 
survived and there was an increase in time to death for the single animal that succumbed to 240 
infection (tab 1). 241 
This increased protection was mirrored by an increase in the magnitude of the anti-rPA83-IgG and -242 
IgG1 titres (fig. 1) in that they significantly exceeded those of the single vectors although they were 243 
still significantly lower than those seen in animals who had received protein vaccines containing 244 
rPA83. The enhanced antibody titres against rPA83 were not associated with a higher NT50-titre 245 
11 
suggesting that the immune response was directed against other epitopes, possibly targets that 246 
promote opsonization or inhibit germination. While the boost in anti-rPA83 titres as a consequence 247 
of co-administration of spore antigens has been seen previously, it was in animals who had been 248 
immunised with a protein formulation [44]. Our corresponding protein combination did not mimic 249 
this trend. 250 
 The anti-rLF-IgG titres observed following co-administration were on the whole similar to those 251 
seen after immunisation with TPA-LFD1PAD4-mIPS-1 alone and showed less scattering. The NT50-252 
titre correlated strongly with anti-rLF-IgG (rs = +0.85) and -IgG1 titres (rs = +0.918) and weakly 253 
with anti-rPA83 IgG and -IgG1 titres (rs ≥ +0.61). This was also true when TPA-LFD1PAD4-mIPS1 254 
was given alone although the correlations were much weaker, thus the tna was positively influenced 255 
for both parts of the antigen alike when combined with BclA under the presence of both adjuvants 256 
while the overall titres generated were diversified. 257 
Surprisingly the anti-rBclA titre of the DNA-vaccine combination and to a lesser extend that of the 258 
protein combination, was significantly lower than that seen for either single vaccine application 259 
(fig. 2). While an antagonistic effect of BclA on PA titre has been observed in other studies and has 260 
been ascribed in part to ―antigenic competition‖ [14][46][44] a negative effect of PA on BclA titres, 261 
as seen here, has not been reported. Apart from the possibility of DNA-vector interferences [45] and 262 
the possible influence of the presence of the adjuvant mIPS-1 in addition to CIITA we have no 263 
explanation for this phenomenon. 264 
However, the overall individual titres measured for the DNA-combination showed less scattering 265 
within the group compared to the titres seen in the groups given a single vector. Thus BclA and PA 266 
given together might have a balancing effect leading to a more stable immune response which 267 
might contribute to enhanced survival. 268 
In conclusion a DNA vaccine comprising a combination of plasmids encoding spore and toxin 269 
targets conferred significantly greater protection than that seen for the individual DNA plasmids 270 
12 
(P ≤ 0.042), the single protein components (P ≤ 0.00008) and the vectors tested in our previous 271 
study [40]. Furthermore it was found to be as effective as a comparable protein combination 272 
(P = 0.251). To our knowledge this is the first example of a vaccination strategy against Anthrax in 273 
which the protective immunity achieved using a DNA based approach exceeded that seen with 274 
protein equivalents [40]. 275 
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PA IgG LF IgG BclA IgG TNA
Protein vaccination
Lipopeptide adjuvant <200 n.d. <200 <100 0%
 e
(0/5)
 e
4.2 ± 3.3
Lipopeptide + rBclA <200 n.d. 257066 ± 149351 <100 10%
 e
(1/10)
 e
3.4 ± 0.7
Lipopeptide + rPA83 561803 ± 113102 n.d. <200 14564 ± 4543 10%
 e
(1/10)
 e
3.7 ± 1.4
Lipopeptide + rBclA + rPA83 415030 ± 199480 n.d. 123442 ± 42637 15581 ± 9683 70%
 e
(7/10)
 e
5.2 ± 3.2
DNA vaccination
CIITA 
a
<200 <200 <200 <100 0% 
f
(0/5) 
f
3.1 ± 0.7
TPA-LFD1PAD4-mIPS1 
a
22488 ± 28511 80682 ± 93200 <200 691 ± 772 30% 
f
(3/10) 
f
4.1 ± 1.2
CIITA + TPA-LFD1PAD4-LAMP1 
b
2135 ± 4065 14443 ± 9708 <200 <100 40% 
f
(4/10) 
f
4.2 ± 0.7
CIITA + TPA-PA83-LAMP1 
b
31645 ± 26067 <200 <200 239 ± 524 30% 
f
(3/10) 
f
4.0 ± 1.0
CIITA + TPA-BclAD1D3-LAMP1 
b
<200 <200 166381 ± 106094 <100 50% 
f
(5/10) 
f
4.2 ± 1.6
CIITA + BclAD1D3-Ubiquitin 
b
<200 <200 221171 ± 150564 <100 50% 
f
(5/10) 
f
4.5 ± 1.7
CIITA + TPA-LFD1PAD4-mIPS1 + TPA-BclAD1D3-LAMP1 
c
60015 ± 32158 57728 ± 37181 34528 ± 15256 463 ± 682 90% 
f
(9/10) 
f
9.0 ± 0.0
a
 immunisation with uniform bullets, resulting in a dose of 3 µg per vector per immunisation
b
 immunisation with mixed bullets (1:1) reducing the effectively applied amount of each vaccine vector to 1.5 µg per vaccination
c
 immunisation with mixed bullets (1:2:1) reducing the effectively applied amount of each vaccine vector to 1.5, 3 and 1.5 µg respectively per vaccination
d
 group mean IgG or NT50 titres ± standard deviation before the challenge
e
 protein groups were challenged with 50LD50 
f
 DNA groups were challenged with 25LD50 
g
 time to death in days post challenge ± standard deviation
Groups
Antibody titres 
d Vaccine 
efficacy (%)
survivors 
/ total
Mean time to 
death 
g
Table 1





